Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.52 |
| ▸ | IGF1R | P08069 | 9/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 7/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | PRKCG | P05129 | 2/20 | 0.49 |
| ▸ | PRKCB | P05771 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | PRKCA | P17252 | 2/20 | 0.49 |
| ▸ | PRKCH | P24723 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 2/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580360 | 0.86 | KDR (0.50) | EGFR | |
| SCHEMBL4580743 | 0.86 | KDR (0.50) | ALKIGF1RIKBKBCHUK | |
| SCHEMBL4579436 | 0.85 | FLT1 (0.52) | ALKIGF1RPRKD3PRKCGEGFR | |
| SCHEMBL4582376 | 0.85 | KDR (0.43) | ALKPRKCGPRKCAPRKCDEGFR | |
| SCHEMBL4581286 | 0.82 | IDH1 (0.41) | — | |
| SCHEMBL4581040 | 0.82 | KDR (0.51) | ZAP70EGFR | |
| SCHEMBL4580865 | 0.81 | MAPK14 (0.42) | EGFR | |
| SCHEMBL4580975 | 0.81 | IKBKB (0.41) | ALKIKBKBCHUK | |
| SCHEMBL4580811 | 0.80 | KDR (0.51) | ALKIGF1RPRKCAPRKCD | |
| SCHEMBL4582327 | 0.80 | HDAC1 (0.47) | PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | ALK 8/4885IGF1R 207/4885ZAP70 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.